Filing Analysis
Organogenesis Holdings Inc. entered into a stock repurchase agreement to buy back 500,000 shares of Class A common stock from the GN 2016 Family Trust at $4.057 per share. The transaction involves a board member as a beneficial owner of the selling entity.
🚩 Red Flags
- Related-party transaction: The shares are being repurchased from an entity controlled by a Board member (Glenn H. Nussdorf).
- Potential use of capital: Using proceeds from recent preferred stock issuance to fund a share repurchase can sometimes be viewed as using new equity capital to exit existing shareholders.
📋 Key Facts
- Repurchase amount: 500,000 shares of Class A common stock.
- Purchase price: $4.057 per share (based on 10-day trailing VWAP as of Nov 26, 2024).
- Counterparty: GN 2016 Family Trust u/a/d August 12, 2016.
- Insider connection: Glenn H. Nussdorf, a member of the Board of Directors, is a beneficial owner of the shares held by the Selling Stockholder.
- Funding source: Proceeds from the Nov 12, 2024 sale of Series A Convertible Preferred Stock to Avista Healthcare Partners III, L.P. and AHP III Orchestra Holdings, L.P.
- Expected closing date: On or around December 3, 2024.
Organogenesis Holdings Inc. entered into a long-term triple net lease for approximately 122,000 square feet of manufacturing space in Smithfield, Rhode Island. The facility is intended to expand the company's production capacity.
🚩 Red Flags
- Triple net lease increases operational expense volatility as the company is responsible for taxes and operating expenses.
- Potential $1.25 million penalty if tax incentives are not secured by March 31, 2025.
- Risk of build-out delays or cost overruns mentioned in forward-looking statements.
📋 Key Facts
- Lease term: Approximately 16.5 years (Nov 18, 2024 – May 31, 2041) with two 10-year renewal options.
- Premises size: ~122,000 square feet at 100 Technology Way, Smithfield, RI.
- Rent structure: Triple net (NNN); base rent of $43.00/sq ft starting June 1, 2026, with a 3% annual increase thereafter.
- Build-out requirement: Company must complete build-out within 36 months; landlord to provide an allowance to offset costs.
- Termination clause: Right to terminate if certain state/local tax incentives are not secured by March 31, 2025 (penalty of $1.25M).
- Purchase option: Includes a one-time right of first offer to purchase the premises.
Organogenesis Holdings Inc. entered into a $130 million subscription agreement to issue 130,000 shares of Series A Convertible Preferred Stock to Avista Healthcare Partners III and an affiliate. The transaction includes a significant $23.5 million repurchase of common stock from existing directors/affiliates and requires the full prepayment of a $62.5 million term loan.
🚩 Red Flags
- Significant dilution potential due to high conversion ratio (263.7x).
- Related-party transactions: $23.5 million used to repurchase shares from directors and former directors.
- Complex capital structure change involving senior preferred stock with liquidation preference.
- Requirement to file registration statement within 40 days, indicating potential future dilution/selling pressure.
📋 Key Facts
- Total offering amount: $130.0 million for 130,000 shares of Series A Convertible Preferred Stock.
- Conversion ratio: Each share is initially convertible into 263.7358 shares of Common Stock.
- Stock Repurchase: $23.5 million to repurchase 7,421,731 shares of Class A common stock at $3.1597 per share from directors and affiliates.
- Debt Repayment: The company expects to prepay approximately $62.5 million in principal and interest on its Term Loan Facility on November 13, 2024.
- Board Change: Garrett Lustig appointed to the Board as a designee of the Investors; Board size increased to twelve directors.
- Placement Agent: Truist Securities, Inc. (4.0% cash fee).
Organogenesis Holdings Inc. filed an 8-K to furnish its press release regarding the financial results for the fiscal third quarter ended September 30, 2024.
📋 Key Facts
- Report date: November 12, 2024
- Reporting period: Fiscal third quarter ended September 30, 2024
- The filing incorporates a press release via Exhibit 99.1 regarding results of operations and financial condition.
Organogenesis Holdings Inc. filed an 8-K to furnish its press release announcing financial results for the fiscal second quarter ended June 30, 2024.
📋 Key Facts
- The filing pertains to the fiscal second quarter ended June 30, 2024.
- Results were announced via press release on August 8, 2024.
- The announcement is furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18 liabilities.
Organogenesis Holdings Inc. reported the results of its 2024 Annual Meeting of Stockholders held on June 20, 2024. Shareholders approved several key items, including the election of directors and an amendment to increase shares reserved for the 2018 Equity Incentive Plan.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Annual Meeting held on June 20, 2024, with 109,048,425 shares represented.
- Stockholders approved an amendment to the 2018 Equity Incentive Plan to increase reserved Class A common stock by 15,900,000 shares.
- Eleven directors were elected to serve until the next Annual Meeting.
- Shareholders approved the advisory 'Say-on-Pay' compensation for named executive officers (63,842,175 votes in favor).
- Stockholders ratified the appointment of RSM US LLP as independent auditors for fiscal year 2024.
Organogenesis Holdings Inc. filed an 8-K to announce its financial results for the fiscal first quarter ended March 31, 2024. The filing serves as a formal notice that the company's quarterly earnings press release is being furnished to the SEC.
📋 Key Facts
- Reporting period: Fiscal first quarter ended March 31, 2024.
- Filing date: May 9, 2024.
- The filing incorporates a press release (Exhibit 99.1) regarding results of operations and financial condition.
Organogenesis Holdings Inc. announced that a U.S. District Court has dismissed a securities fraud lawsuit against the company and its top executives with prejudice.
🚩 Red Flags
- None identified; this is a resolution of a legal liability rather than an emergence of one.
📋 Key Facts
- On March 29, 2024, the U.S. District Court for the Eastern District of New York granted a motion to dismiss all claims in a securities fraud case.
- The dismissal was granted 'with prejudice,' meaning the plaintiffs cannot refile the same claims.
- The lawsuit targeted Organogenesis Holdings Inc., its CEO, and its CFO.
Organogenesis Holdings Inc. filed an 8-K to announce its financial results for the fiscal fourth quarter and full year ended December 31, 2023. The filing serves as a formal mechanism to furnish the press release containing these earnings results.
📋 Key Facts
- Reporting period: Fiscal fourth quarter and year ended December 31, 2023.
- Filing date: February 29, 2024.
- The filing incorporates a press release via Exhibit 99.1 to communicate results of operations and financial condition.